Daito Pharmaceutical Co., Ltd. Logo

Daito Pharmaceutical Co., Ltd.

Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.

4577 | T

Overview

Corporate Details

ISIN(s):
JP3486150000
LEI:
Country:
Japan
Address:
富山市八日町326番地
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Daito Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and sale of pharmaceutical products. The company operates an integrated business model that covers the entire production process, from active pharmaceutical ingredients (APIs) to finished formulation products, including powders, granules, and tablets. Its portfolio consists of generic drugs (both prescription and over-the-counter), health foods, and quasi-drugs. In addition to its own products, Daito serves other pharmaceutical firms by supplying APIs for generic products and offering contract manufacturing (CMO) services. The company emphasizes a stable supply of high-quality products managed by a strict quality assurance system.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:52
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.5 KB
2025-08-27 08:15
Registration Form
確認書
Japanese 8.3 KB
2025-08-27 08:13
Annual Report
有価証券報告書-第83期(2024/06/01-2025/05/31)
Japanese 1.4 MB
2025-06-12 09:16
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.3 KB
2025-05-13 09:22
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.0 KB
2025-04-11 08:53
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 25.3 KB
2025-03-12 08:08
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.7 KB
2025-02-13 08:56
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.2 KB
2025-01-17 09:04
M&A Activity
臨時報告書
Japanese 34.3 KB
2025-01-10 08:56
Report Publication Announcement
確認書
Japanese 8.3 KB
2025-01-10 08:54
Interim Report
半期報告書-第83期(2024/06/01-2025/05/31)
Japanese 194.9 KB
2024-09-02 08:00
Post-Annual General Meeting Information
臨時報告書
Japanese 21.8 KB
2024-08-30 07:43
Registration Form
確認書
Japanese 8.2 KB
2024-08-30 07:41
Governance Information
内部統制報告書-第82期(2023/06/01-2024/05/31)
Japanese 22.1 KB
2024-08-30 07:38
Annual Report
有価証券報告書-第82期(2023/06/01-2024/05/31)
Japanese 1.3 MB

Automate Your Workflow. Get a real-time feed of all Daito Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Daito Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Daito Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

C4 Therapeutics, Inc. Logo
Developing protein degrader medicines to treat cancer and other serious diseases.
United States of America
CCCC
Cabaletta Bio, Inc. Logo
Develops engineered T cell therapies for a curative reset in autoimmune diseases.
United States of America
CABA
Cadrenal Therapeutics, Inc. Logo
Developing novel anticoagulant therapies for high-risk cardiovascular patients.
United States of America
CVKD
CalciMedica, Inc. Logo
Develops CRAC channel inhibitors for critical illnesses like acute pancreatitis & AKI.
United States of America
CALC
Calidi Biotherapeutics, Inc. Logo
Develops immunotherapies using stem cells to deliver oncolytic viruses against solid tumors.
United States of America
CLDI
Calliditas Therapeutics Logo
Develops and commercializes novel treatments for rare renal and hepatic diseases like IgA nephropathy.
Sweden
CALTX
CALTH. Inc Logo
Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.
South Korea
402420
CAMBRIDGE NUTRITIONAL SCIENCES PLC Logo
Develops and manufactures diagnostic tests for food sensitivity and gut health.
United Kingdom
CNSL
Camp4 Therapeutics Corp Logo
Developing RNA-based therapies to upregulate genes for rare metabolic and CNS disorders.
United States of America
CAMP
Camurus Logo
Develops long-acting medicines for severe chronic diseases using advanced drug delivery.
Sweden
CAMX

Talk to a Data Expert

Have a question? We'll get back to you promptly.